Clinical Trials Logo

Clinical Trial Summary

Fractionated laser resurfacing is commonly used as a treatment for acne scarring in fair skinned individuals. This study aims to test the efficacy and safety in darker skin types. Patients are randomized to either the 10mJ 40mJ dosages and receive a total of five treatments at 17% one month apart. Improvement is judged by a dermatologist as 0-25%, 25-50%, 50-75% or 75-100%. Side effects such as pigmentary abnormalities and pain are also evaluated.


Clinical Trial Description

Background: Ablative resurfacing lasers are effective for treatment of acne scars, but they have a high risk of complications. Fractional lasers have less severe side effects but more moderate efficacy than ablative devices. Studies were performed in individuals with Fitzpatrick skin type I to VI. Objective: To determine the efficacy and safety of an erbium 1,550-nm fractional laser in the treatment of facial acne scars in Fitzpatrick skin types IV to VI. Methods: We conducted a prospective, single-blind, randomized trial in patients with acne scars (n=15), skin type IV to VI, with a 1,550-nm erbium fractionated laser. Patients were divided into two groups; one was treated with 10 mJ and the other with 40 mJ. Five monthly laser sessions were performed. A patient questionnaire was distributed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00641420
Study type Interventional
Source Henry Ford Health System
Contact
Status Completed
Phase N/A
Start date September 2007
Completion date September 2008

See also
  Status Clinical Trial Phase
Completed NCT01644435 - A Pilot Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Acne Scarring Phase 1/Phase 2
Completed NCT00510055 - Treatment of Acne Scarring With a Novel Procedure Combination N/A
Completed NCT05386732 - Safety and Efficacy of the 4MD Micro Needling Device in the Treatment of Acne Scars
Completed NCT02174393 - Microneedling Plus the Universal Peel For Acne Scarring N/A